Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 19, 2024Blood AdvancesOpen Access

Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJulia DriessenAmsterdam University Medical CentersFWFer de WitAmsterdam University Medical CentersAHAlex F. HerreraCity Of Hope National Medical Center

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Driessen et al. (2024) studied this question.

synapsesocial.com/papers/68e734fcb6db6435876ae87dhttps://doi.org/10.1182/bloodadvances.2023012145
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study2020 · 105 citations
  2. 2Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results2021 · 227 citations
  3. 3Performance of matching methods in studies of rare diseases: a simulation study2020 · 27 citations
  4. 4cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity2003 · 940 citations
  5. 5Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma2021 · 208 citations